Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20932771 | 0.90 | GAA (0.42) | KMT2ATDP1MEN1LMNAHTT | |
| SCHEMBL30130167 | 0.90 | GAA (0.42) | KMT2ATDP1MEN1LMNAHTT | |
| SCHEMBL22263137 | 0.79 | MAPK1 (0.50) | KMT2ATDP1MEN1LMNAALDH1A1 | |
| SCHEMBL20932775 | 0.78 | GAA (0.40) | KMT2AMEN1LMNAALDH1A1HPGD | |
| SCHEMBL20917818 | 0.77 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL20932776 | 0.76 | KDM4E (0.49) | KMT2ATDP1MEN1LMNAALDH1A1 | |
| SCHEMBL19061452 | 0.76 | PKM (0.48) | KMT2AMEN1HTTHSD17B10PKM | |
| SCHEMBL20918028 | 0.76 | CYP1A2 (0.44) | KMT2ATDP1MEN1LMNAALDH1A1 | |
| SCHEMBL22263126 | 0.74 | HTT (0.41) | KMT2ALMNAHTTALDH1A1MAPT | |
| SCHEMBL22263119 | 0.74 | ALDH1A1 (0.43) | KMT2AMEN1LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | KMT2A 800/4885TDP1 637/4885MEN1 1174/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KMT2A 800/4885TDP1 637/4885MEN1 1174/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KMT2A 800/4885TDP1 637/4885MEN1 1174/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | KMT2A 796/4885TDP1 652/4885MEN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.